Europe's First CAR-T Production Site Approaches Final Construction Milestone
A delegation from UGent and Janssen is given a tour of the brand new CAR-T production site at Gent Tech Lane Science Park.
(23-06-2023)
The 1st European CAR-T production site, located at Ghent Tech Lane Science Park is currently in its final construction phase. This cutting-edge facility represents a significant milestone in the longstanding and solid collaboration between U(Z)Gent, Janssen Belgium, and Legend Biotech.
This milestone showcases the fruitful alliance between these renowned institutions and highlighted their shared commitment to revolutionizing cancer treatment. The partnership's core focus lies in advancing immune-oncology research and translating scientific breakthroughs into tangible therapeutics.
The forthcoming CAR-T production site is designed to operate under stringent Good Manufacturing Practices (GMP) conditions and equipped with state-of-the-art clean rooms, the facility will employ hundreds of talented professionals meticulously trained for their specific roles. This strategic investment not only drives talent development but also bolsters the regional economy.
At the heart of this endeavor is the shared commitment to advancing the field of immune-oncology. By combining the expertise of UGent, UZGent, and Janssen, we aim to push the boundaries of innovation and improve patient outcomes in the battle against cancer.